Human NEK9 knockout A-431 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
NEK9 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 10 bp deletion, 2 bp deletion; Frameshift: 99.78%.
View Alternative Names
APUG, DKFZp434D0935, KIAA1995, LCCS10, MGC138306, MGC16714, NC, NEK9_HUMAN, NERCC, NERCC1, NIMA (never in mitosis gene a) related kinase 9, NIMA related kinase 9, NIMA related kinase Nek8, NIMA-related kinase 8, Nercc 1 kinase, Never in mitosis A-related kinase 9, NimA-related protein kinase 9, Serine/threonine-protein kinase Nek9
- WB
Lab
Western blot - Human NEK9 knockout A-431 cell lysate (AB270497)
Lane 1 : Wild-type A431 cell lysate 20 ug
Lane 2 : NEK9 knockout A431 cell lysate 20 ug
Lane 3 : Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate 20 ug
Lane 4 : MCF7 (Human breast adenocarcinoma cell line) whole cell lysate 20 ug
Lanes 1 - 4 : Merged signal (red and green). Green - ab138488 observed at 120 kDa. Red - loading control, ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55kDa.
ab138488 was shown to react with NEK9 in wild-type A-431 cells in western blot Loss of signal was observed when NEK9 knockout cell line ab270474 (knockout cell lysate ab270497) was used. Wild-type and NEK9 knockout A-431 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab138488 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-NEK9 antibody [EP7361] (<a href='/en-us/products/primary-antibodies/nek9-antibody-ep7361-ab138488'>ab138488</a>) at 1/1000 dilution
Lane 1:
Wild-type A-431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2:
NEK9 knockout A-431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2:
Western blot - Human NEK9 knockout A-431 cell line (<a href='/en-us/products/cell-lines/human-nek9-knockout-a-431-cell-line-ab270474'>ab270474</a>)
Lane 3:
Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg
Lane 4:
MCF7 (Human breast adenocarcinoma cell line) whole cell lysate at 20 µg
Predicted band size: 107 kDa
Observed band size: 120 kDa
false
- NGS
Supplier Data
Next Generation Sequencing - Human NEK9 knockout A-431 cell lysate (AB270497)
Knockout achieved by CRISPR/Cas9; X = 10 bp deletion, 2 bp deletion; Frameshift : 99.78%
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
This protein modulates different aspects of mitosis particularly in spindle formation and chromosome segregation. NEK9 forms a part of a complex in conjunction with other kinases like NEK6 and NEK7 coordinating the early events of mitosis. Its activity supports centrosome separation and microtubule nucleation which are important for proper cell division.
Pathways
NEK9 is involved in the cell cycle and microtubule organization pathways. It works in conjunction with proteins such as PLK1 and Aurora A which regulate the entry and progression through mitosis. NEK9 activates NEK6 and NEK7 which further propagate signals necessary for mitotic spindle assembly ensuring efficient cell division.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female
Complementary Products
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NEK9 antibody [EP7361] (AB138488)](https://content.abcam.com/products/images/nek9-antibody-ep7361-ab138488--immunohistochemistry-formalin-pfa-fixed-paraffin-embedded-sections-img59842.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com